Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
Status:
Completed
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI;
PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with
placebo.